Nektar Therapeutics (NASDAQ: NKTR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.680 | -0.490 | 0.1900 | ||||
REV | 24.380M | 24.822M | 442.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Nektar Therapeutics (NASDAQ: NKTR) through any online brokerage.
Other companies in Nektar Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), CinCor Pharma (NASDAQ:CINC) and Sundial Growers (NASDAQ:SNDL).
The latest price target for Nektar Therapeutics (NASDAQ: NKTR) was reported by Jefferies on Tuesday, May 31, 2022. The analyst firm set a price target for 4.00 expecting NKTR to rise to within 12 months (a possible 6.67% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Nektar Therapeutics (NASDAQ: NKTR) is $3.75 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Nektar Therapeutics.
Nektar Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Nektar Therapeutics.
Nektar Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.